RecruitingPhase 2NCT05987124
Defibrotide Dose-escalation for SOS Post-HSCT
Studying Hepatic veno-occlusive disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Medical College
- Principal Investigator
- Mitchell Cairo, MDNew York Medical College
- Intervention
- Defibrotide(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- New York Medical College, Valhalla, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05987124 on ClinicalTrials.govOther trials for Hepatic veno-occlusive disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06715046Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell TransplantationUniversity of Turin, Italy
- RECRUITINGNCT05090345A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).Duke University
- ACTIVE NOT RECRUITINGNANCT03865589Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction SyndromeChildren's Mercy Hospital Kansas City